NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Corxel

Corxel

Private
ShanghaiHealthcare & Life Scienceshttps://corxel.com/

Last Round

Series D

Extension

Jan 22, 2026

Total Funding Raised

$489M

Company Overview

Corxel is a biopharmaceutical company that in-licenses and develops clinical-stage assets to treat cardiometabolic and cardiovascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentclinical trialscardiometabolic diseasein-licensingsmall-molecule drugsGLP-1 receptor agonistbiotech pipelineasset-focused biotechclinical-stagepharma licensingdrug discoveryobesity treatmentGreater China commercializationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Corxel Comparables

Compare Corxel with similar companies based on industry and business-model similarity.

Corxel comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zhejiang Jixing Auto Parts Co., Ltd.
97%
Gmax Biopharm
81%
Sciwind Biosciences
80%

Corxel Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionJan 22, 2026
Series DJan 6, 2024
Series CSep 1, 2021
Series BJul 13, 2021

Corxel Investors

Notable investors and investment history

Corxel investors
InvestorRounds
Hengdian Group CapitalSeries D Extension
SymBiosis Capital ManagementSeries D Extension
RA Capital ManagementSeries D Extension
TCG CrossoverSeries D Extension
HBM Healthcare InvestmentsSeries D Extension
Adage Capital ManagementSeries D Extension
SilverArc Capital ManagementSeries D Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2024

    $162M round led by Leaps by Bayer and RTW Investments.

Corxel Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Corxel Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Corxel's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2019
Last FundingJan 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.